

Artikel osteoporose:

- Reference List

(1) Graat-Verboom L, Wouters EF, Smeenk W, van den Borne BE, Lunde R, Spruit MA. Current status of research on osteoporosis in COPD: a systematic review. *Eur Respir J*. 2009;34:209-218.

(2) WHO Scientific Group on the Prevention and Management of Osteoporosis. Prevention and Management of Osteoporosis: report of a WHO scientific group. http://whqlibdoc.who.int/trs/WHO_TRS_921.pdf . 13-9-2007.
Ref Type: Electronic Citation

(3) Genant HK, Delmas PD, Chen P et al. Severity of vertebral fracture reflects deterioration of bone microarchitecture. *Osteoporos Int*. 2007;18:69-76.

(4) Genant HK, Wu CY, van KC, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. *J Bone Miner Res*. 1993;8:1137-1148.

(5) Graat-Verboom L, van den Borne BE, Smeenk FW, Spruit MA, Wouters EF. Osteoporosis in COPD outpatients based on bone mineral density and vertebral fractures. *J Bone Miner Res*. 2011;26:561-568.

Artikel Indacaterol:

Dahl R, et al. Efficacy of a new once-daily long-acting inhaled β_2 -agonist indacaterol versus twice-daily formoterol in COPD. *Thorax* 2010; 65: 473-479.

Kornmann O, et al. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. *Eur Respir J* 2010; Aug 6 epub.

Vogelmeier C, et al. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. *Respiratory Research* 2010, 11:135.

European Medicines Agency Assessment report for onbrez inhaler 2009.

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001114/WC500053735.pdf

Artikel SLIT

Referenties

1. Bousquet J, Lockey R, Malling HJ. *Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper.* *J Allergy Clin Immunol*, 1998. 102(4 Pt 1): p. 558-62.
2. Valovirta E, Jacobsen L, Ljorring C, et al. *Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.* *Allergy*, 2006. 61(10): p. 1177-83.
3. Wahn U, Tabar A, Kuna P, et al. *Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis.* *J Allergy Clin Immunol*, 2009. 123(1): p. 160-166 e3.
4. Bufe A, Eberle P, Franke-Beckmann E, et al. *Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.* *J Allergy Clin Immunol*. 2009;123:167-173.
5. Halken S, Agertoft L, Seidenberg J, et al. *Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents.* *Pediatr Allergy Immunol*, 2010, 21(6):970-6
6. Durham SR, Emminger W, Kapp A, et al. *Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet.* *J Allergy Clin Immunol*. 2010 Jan;125(1):131-8.e1-7.
7. Ciprandi G, Cadario G, Di Gioacchino GM, et al. *Sublingual immunotherapy in children with allergic polysensitization.* *Allergy Asthma Proc*. 2010 May-Jun;31(3):227-31.
8. Ciprandi G, Incorvaia C, Puccinelli P, et al. *The POLISMAIL lesson: sublingual immunotherapy may be prescribed also in polysensitized patients.* *Int J Immunopathol Pharmacol*. 2010 Apr-Jun;23(2):637-40.
9. Marogna M, Spadolini I, Massolo A, et al. *Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients.* *Ann Allergy Asthma Immunol*. 2007 Mar;98(3):274-80.